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Background: Nephrotic syndrome is one of the most commonly diagnosed kidney diseases in childhood and its
progressive forms can lead to chronic kidney disease (CKD) and/or end-stage renal disease (ESRD). There have been
few longitudinal studies among a multi-ethnic cohort to determine potential risk factors influencing disease
susceptibility, treatment response, and progression of nephrotic syndrome. Temporal relationships cannot be
studied through cross-sectional study design. Understanding the interaction between various factors is critical to
developing new strategies for treating children with kidney disease. We present the rationale and the study design
of a longitudinal cohort study of children with nephrotic syndrome, the Insight into Nephrotic Syndrome:
Investigating Genes, Health and Therapeutics (INSIGHT) study. The specific aims are to determine: 1) socio-
demographic, environmental, and genetic factors that influence disease susceptibility; 2) rates of steroid treatment
resistance and steroid treatment dependence, and identify factors that may modify treatment response; 3) clinical
and genetic factors that influence disease susceptibility and progression to CKD and ESRD; and 4) the interaction
between the course of illness and socio-demographic, environmental, and clinical risk factors.
Methods/design: INSIGHT is a disease-based observational longitudinal cohort study of children with nephrotic
syndrome. At baseline, participants complete questionnaires and provide biological specimen samples (blood, urine,
and toenail clippings). Follow-up questionnaires and repeat biological specimen collections are performed annually
for up to five years.
Discussion: The proposed cohort will provide the structure to test various risk factors predicting or influencing
disease susceptibility, treatment response, and progression to CKD among children with nephrotic syndrome.
Trial registration: ClinicalTrials.gov Identifier NCT01605266.
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Idiopathic nephrotic syndrome is a commonly diagnosed
kidney disease in childhood and treatment resistant forms
can result in scarring of the kidney, eventually progressing
to chronic kidney disease (CKD) and/or end stage renal dis-
ease (ESRD) [1]. Nephrotic syndrome occurs when changes
in the permselectivity barrier of the glomerular capillary wall
can no longer restrict the loss of protein to a minimal level,
thus resulting in massive protein loss through the urine [2].
Nephrotic syndrome can result in lethal infections, throm-
bosis, and pulmonary edema as a result of the significant
protein loss [2]. The estimated incidence of nephrotic syn-
drome is between 2-7 per 100,000 children worldwide, with
higher rates reported among those with African and South
Asian ancestry [2-6]. The specific causes of nephrotic syn-
drome are disputed, but are considered to be immune-
mediated based on the evidence that steroids treat the
underlying disease, and on observed associations of neph-
rotic syndrome with atopy. Prior to the initiation of steroid
treatment in the 1960s, the risk of morbidity and mortality
was extremely high [7]. Most common clinical protocols
provide at least 12-16 weeks of steroid therapy at diagnosis,
followed by second line agents if the child is deemed steroid
resistant, steroid dependant, or a frequent relapser. Current
clinical convention is that the initial response to steroids will
determine the long-term risk of disease progression; how-
ever, approximately 20% of children with nephrotic syn-
drome will not respond to steroids among those with
European ancestry, and the rates of steroid treatment resist-
ance are reported to be significantly higher among those
with African (≈16-27%) and Asian (≈27-54%) ancestry
(Table 1) [2-6,17,18].
There have been very few longitudinal cohort studies of
children with nephrotic syndrome (Table 1). Most cohort
studies are retrospective chart reviews, limited by access to
clinical data that have been recorded and are available. The
few prospective studies on childhood nephrotic syndrome
are largely registries with short follow-up time and limited
clinical information. Existing cohort studies are limited to
ethnically homogenous populations, which preclude the
ability to test if there are true differences in treatment re-
sponse among ethnicities, or if this observed difference is a
result of bias from highly selected populations or differ-
ences among pediatric nephrology practices. However, this
could be tested in a cohort study involving a diverse group
of children treated under the same clinical protocol.
There is also an emerging picture of the role of genetics
in nephrotic syndrome. In 2008, the gene, MYH9, was
found to explain both the higher rates of focal segmental
glomerulosclerosis (FSGS), a steroid-resistant form of
nephrotic syndrome, and the higher rates of ESRD among
African Americans compared to European Americans
[19,20]. FSGS and ESRD were also linked to an adjacent
gene on the chromosome 22 locus, APOL1, in 2010 [21].The odds of having advanced kidney disease are 2-7 times
greater for those carrying risk alleles of either MYH9 or
APOL1, as compared to controls [19,20]. APOL1 has also
been linked to HIV-associated nephropathy [22]. The
chromosome 22 locus is also associated with both kidney
disease susceptibility and kidney disease progression among
Europeans; however, the allele frequency is low and thus
cannot be used for clinical screening of progression [23].
Moreover, the APOL1 allele frequency varies depending on
ancestry, but studies have yet to determine if those of Asian
or South Asian heritage are at higher risk than those of
other ethnic backgrounds [24]. Genetic factors may play a
significant role in the development of disease among chil-
dren, as there is limited time for exposure to non-genetic
factors that influence disease risk as in adults.
It is likely that both genetic and environmental factors
are involved in the onset and course of nephrotic syn-
drome. The onset of nephrotic syndrome has been linked
to environmental influences such as mercury exposure (in
adults), history of atopy, and immune response [25-28].
Renal effects have been found in children as a result of
low-level exposures to cadmium, lead, mercury, and ar-
senic, but the role of these exposures in nephrotic syn-
drome has never been explicitly identified [29]. There is a
small body of literature describing the associations between
childhood nephrotic syndrome and socio-demographic fac-
tors, but they are mostly cross-sectional studies or pro-
spective studies with limited follow-up, thus restricting our
understanding of the determinants of health for children
with nephrotic syndrome and their families due to limita-
tions in study design and follow-up [30-39]. As a result,
there is a significant gap in the literature on the role of en-
vironmental and socio-demographic modifiers of nephrotic
syndrome in children in the long-term. Socio-demographic
factors such as economic status, child quality of life and
parental well-being, environmental factors such as expo-
sures to lead or heavy metals, and serological modifiers,
clinical factors such as hypertension or body mass index,
or genetic factors may account for the variability in inci-
dence and progression rates among various ethnic groups.
A prospective cohort that addresses these variables would
allow researchers to address temporal association to detect
gene or gene-environment interactions that cannot be
identified in case–control or cross-sectional study designs
[40]. For example, if genetic screening in children could
identify those that will have worse outcomes and an
increased likelihood of progression, current clinical strat-
egies will be challenged and alternative treatments to delay
progression may be considered, such as the use of antihy-
pertensive medications [41].
Insight into Nephrotic Syndrome: Investigating Genes,
Health, and Therapeutics (INSIGHT) is a longitudinal
study established to test for factors influencing disease
susceptibility, treatment response, and progression to
Hussain et al. BMC Nephrology 2013, 14:25 Page 3 of 11
http://www.biomedcentral.com/1471-2369/14/25CKD and ESRD among children with nephrotic syn-
drome. Understanding the interaction between socio-
demographic, environmental, clinical, and genetic factors
over time is critical to developing new strategies for
treating children with nephrotic syndrome. This paper
describes the study design of INSIGHT, and discusses
the potential implications of its research.
Methods and study design
Study centre
INSIGHT is a disease-based, observational longitudinal
cohort study primarily based at The Hospital for Sick
Children (SickKids) in Toronto, Canada. Since 1993,Table 1 Observational Studies in Children with Nephrotic Syn
Author Year N Ethnicity Mean
SD
Retrospective Studies
Ingulli [5] 1991 177 Black & Hispanic
65 Caucasian
Bircan [8] 2002 138 Turkish
Ozkaya [9] 2004 392 Turkish
Kim [10] 2005 103 Caucasian
96 African-American
Bhimma [3] 2006 816 Black & Indian
Chang [11] 2009 99 Chinese
Mubarak [6] 2009 538 Pakistani
Otukesh [12] 2009 73 Iranian
Copelovitch [4] 2010 112 Cambodian
Banaszak [13] 2012 76 Caucasian (Poland)c
102 Caucasian (Poland)d
Prospective Studies
Kumar [14] 2003 290 Northern and Eastern Indian
Wong [15] (Registry) 2007 49 New Zealand European,
Maori, Pacific Islander, Asian, Other
Bakkali [16] (Registry) 2011 231 No data (Netherlands)
a indicates age of study group, where age at onset not specified.
b estimated based on participants diagnosed with FSGS.
c indicates patients treated with NS between 1986-1995.
d indicates patients treated with NS between 1996-2005.
e no steroid resistance reported.there has been a nurse-managed, out-patient program to
teach patient and families self-monitoring and treatment
of relapses from nephrotic syndrome. This program uses
a validated electronic data system to track basic clinical
information and relapses throughout the clinical follow-
up period of each child. Staff physicians oversee the
program and direct the decision-making surrounding
medication dosage and patient care plans. A standard
treatment protocol was implemented and developed
nearly 20 years ago based on consensus of staff physi-
cians and revised in 2000 for the treatment of relapses.
The protocol involves an initial 16 weeks of steroid
therapy with prednisone, comprised of a maximum ofdrome
Age at Onset ±
, yrs (Range)




7.3 ± 4.6 No data 8.25 ± 4.3 15.3%
(1.0-16.75) (1-15)
7.8 ± 4.8 8.8 ± 4.1 6.2%
(2-14.8) (2-14.8)
4.9 ± 3.56 61.2% 3.4 ± 2.31 13.2%
(1-15) (1-6)
4.6 ± 3.4 59.2% 2 23%b
(0.9-16)a
4.3 ± 3.5 51% No data 3.6%
8.2 ± 5.2 No data 11%
4.8 60.4% 2.5 27.3%
(1.2-16) (0.1-16.5)
8.35 ± 4.61 73.7% 5.06 ± 4.35 N/Ae
(2-18)
9.79 ± 4.59 64.4% No data 31.1%
(0.8-18)a
5.9 52.0% 6.0 ± 4.2 100%
(0.5-16)
8.95 63.4% 15.1 6.25%
(0.6-15.75) (3.7-2.73)
2.7 (median) 54.5% No data 15.8%
3.3 (median) 68% No data 31.3%
7.9 ± 5.1 73.4% No data 38%b
6.1 ± 3.8 71.4% 1 19.6%
5.08 67.1% 4 N/Ae
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40 mg/m2 every other day for 6 weeks, 30 mg/m2 every
other day for 8 days, 20 mg/m2 every other day for 8 days
and finally 10 mg/m2 every other day for 12 days before
stopping steroid treatment. A standard protocol is also
used for the treatment of relapses. This is followed by
second-line agents if the child is deemed steroid resist-
ant, steroid dependant, or a frequent relapser, and is
decided on a case-by-case basis.Figure 1 Conceptual model of nephrotic syndrome disease pathwayAims
Aims of INSIGHT are to determine 1) genetic and envir-
onmental factors that influence susceptibility to neph-
rotic syndrome among a multi-ethnic group of children;
2) rates of steroid treatment resistance and steroid treat-
ment dependence, and the influence of ethnicity as a
treatment modifier in children with nephrotic syndrome;
3) clinical and genetic factors that influence progression
of kidney disease to CKD and/or ESRD among childrenand modifiers.
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nephrotic syndrome and socio-demographic, environ-
mental, and clinical modifiers (Figure 1).
Study participants
The study population consists of incident and prevalent
cases of nephrotic syndrome diagnosed or treated at
SickKids after 1993. Participants concurrently followed
in clinic will be seen prospectively by the study for up to
five years, or until they are discharged from clinical care.
Non-concurrent participants are seen once for the study.
The inclusion criteria for participants are: 1) a diagnosis
of presumed idiopathic nephrotic syndrome after the age
of 1 and before age 18; and 2) ability to provide
informed consent or have a parent or guardian provide
informed consent on their behalf; and 3) the parent and
child agreeing to complete questionnaires and to provide
biological samples. Exclusion criteria are: 1) disease with
multiple organ involvement; or 2) conditions such as
systemic lupus erythematosus or vasculitis; or 3) patients
with biopsy-proven membranous glomerulonephritis
(MGN) or membranoproliferative glomerulonephritis
(MPGN). Toronto’s ethnically and socially diverse popu-
lation will allow for the recruitment of a diverse, non-
homogenous cohort of children.
Data and biological specimen collection
Baseline and follow-up questionnaires for concurrent
participants are completed by the child (if able, or by the
parent by proxy) and by a parent or guardian. Baseline
questionnaires for the child and parent or guardian are
completed upon enrollment. Follow-up questionnaires
for the parent or guardian and the child are completed
annually for five years, or until the child has been dis-
charged from clinic. INSIGHT questionnaires make use
of standardized questionnaires that have been tested forTable 2 Outcome Ascertainment for INSIGHT
Clinical
Remission: Urine protein/creatinine < 0.2 or Albustik negative or trace for 3 co
Relapse: After remission, an increase in the first morning urine protein/creatin
Frequently relapsing NS: 4 or more relapses within 1 year OR 2 or more relaps
Steroid dependant NS: Relapse during steroid taper or within 14 days of stero
Steroid resistant: Inability to induce remission within 28 days of steroid therap
Laboratory
Urine protein/creatinine: Abnormal if > 250 mg/mmol
Urine albumin/creatinine: Abnormal if > 30 mg/mol
Creatinine based eGFR: eGFR by modified Schwartz (ml/min/1.73 m2) = k x he
CKD/ESRD: eGFR < 60 ml/min/1.73 m2 (or dialysis)reliability and validity wherever possible, including the
Pediatric Quality of Life Inventory (PEDSQL™-V4), the
McMaster Family Assessment Device (FAD), the short
version of the Patient Health Questionnaire for Depres-
sion and Anxiety (PHQ-4), and the Brief Test of Func-
tional Health Literacy in Adults (S-TOFHLA) [42-46].
Non-concurrent participants complete a basic core ques-
tionnaire upon enrollment with no follow-up. Ethnicity
is self-reported for the child with nephrotic syndrome,
the biological parents and the biological grandparents
(Additional file 1: Appendix 1).
Key clinical outcome data for all participants are
abstracted from each participant’s electronic medical
record. Set definitions are used, according to standard
clinical care. Clinical outcomes include remission, re-
lapse, frequently relapsing nephrotic syndrome, steroid
dependence, and steroid resistance [47,48]. Laboratory
outcomes include urine protein to creatinine ratio, urine
albumin to creatinine ratio, creatinine-based eGFR, and
CKD/ESRD (Table 2).
Concurrent participants provide blood and urine sam-
ples in addition to 3 toenail clippings to test for environ-
mental exposures (i.e. lead or other heavy metals such as
mercury or cadmium). This method has previously been
proven to be good at measuring exposures and is less in-
vasive than extracting hair samples [49]. Baseline sam-
ples are collected as close to enrollment as possible and
annually afterwards to coincide with follow-up. Concur-
rent participants will also perform a 24-hour ambulatory
blood pressure monitor in their second year of the study
to assess the presence of hypertension or pre-
hypertension associated with nephrotic syndrome [50].
Non-concurrent participants provide biological samples
at the time of enrollment. Participants who are unable to
provide a blood sample may provide a saliva sample as
an alternative method of DNA collection (Appendix 1).Follow up time since initial onset
(months)
4 8 12 24 36 48 60
nsecutive days x x x x x x x
ine ≥2 for 3 of 5 consecutive days x x x x x x x
es within 6 months x x x x x
id discontinuation x x x x x x x
y x x x x x
x x x x x x x
x x x x x x x
ight/serum creatinine x x x x x x x
Anytime
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Data are entered into REDCap™, a secure online data
management portal designed for use in research [51]. All
biological specimens are maintained through Freezer-
works™, a biospecimen management software, and
stored locally. Biological specimens are aliquoted and
frozen at -80°C. This protocol was based on guidelines
developed from established biobanking best practices
[52]. Genomic DNA will be extracted from the blood
and saliva samples obtained from participants. Blood
and urine samples will also be tested for factors that
may modify treatment response, such as cytokine levels,
IgE levels, or complement.Sample size & power considerations
Our enrollment target is at least 350 participants from
SickKids and the Greater Toronto Area. We have calcu-
lated the power for a minimum sample size of ~350 par-
ticipants in a longitudinal analyses of time to CKD using
log-rank analyses (Table 3). We demonstrate good power
across the hazard ratios ranging from 1.5-3.0 and by per-
cent exposed as compared to those unexposed to any of
the potential risk factors. These values are consistent
with our preliminary data of frequencies among gender
and age groups of greater than 20%. Additionally, we
have assumed an alpha of 0.05 and a 10% drop out in ei-
ther group over a minimum of 3 years of follow-up. We
have excellent power for hazards greater than 2.0 con-
sistent with candidate genes association with FSGS such
as APOL1.Ethical considerations
INSIGHT has been approved by the Research Ethics
Board at SickKids. Written, informed consent is obtained
from each participant (the parent or guardian and the
child of age to provide consent) prior to commencing any
data collection for the study. All children age 13 or less
provide assent to study participation in addition to parent
or guardian consent. Participants are free to withdraw
from the study at any time. All data collected are linked to
a unique study ID number, and not to any patient identi-
fiers. Due to the sensitive nature of biobanking DNA, only
open consent is received regarding the use of DNA.Table 3 Power Calculation for Survival Analyses*
Prop
350
% exposed 10% 20% 30
Hazard ratio 1.5 0.31 0.59 0.7
2 0.79 0.98 0.9
2.5 0.98 0.99 0.9
*assuming an alpha of 0.05, follow-up over 3 years, and a 10% drop out in either gINSIGHT is also a registered study under the Clinical-
Trials.gov Identifier: NCT01605266.
Results
Recruitment for INSIGHT began in 2011 at SickKids
and is ongoing. As of August 13, 2012, 211 participants
have been recruited into the study (Table 4).
Demographic characteristics
The mean participant age at onset of nephrotic syn-
drome is 5.28 ± 3.89 years. Males account for 60.2% of
participants. Our cohort is, thus far, mostly English-
speaking, with 69.4% of participants reporting that they
always speak English at home.
Most study participants (n = 163, 87.6%) were born in
Canada, however over half of their parents have immi-
grated from elsewhere. Nearly one-third of participants
are classified as from a low-income family using a cut-
off of $35,000, based on the Statistics Canada Low In-
come Measure in 2007 [53]. Primary caregivers are a
well-educated group with on average, 14.5 ± 3.2 years of
schooling.
Ethnicity
Participants self-reported ethnicity for the biological
grandparents, parents, and the child with nephrotic
syndrome into up to four of the following categories:
European/Canadian/American, South Asian, Asian/Pacific
Islander, African, West Indian/Caribbean, Middle Eastern,
South American, and Aboriginal. A mixed background
was defined as participants reporting an ethnic ancestry in
more than one category. Initial ethnic classification for
185 participants for whom self-report data are available
has determined that most of the study population comes
from a European ethnic background (n = 77, 41.6%), fol-
lowed by participants of a mixed (n = 39, 21.1%), or South
Asian (n = 39, 21.1%) background. The remaining are clas-
sified as Asian/Pacific Islander (n = 15, 8.1%) or are from
other ethnic backgrounds (n = 15, 8.1%). We anticipate
that as enrollment increases, the ethnic makeup of our co-
hort will change. This will increase generalizability to
other populations not as ethnically diverse as ours in
Toronto.osed study population
400
% 40% 10% 20% 30% 40%
4 0.8 0.37 0.66 0.8 0.85
9 0.99 0.86 0.99 0.99 0.99
9 1 0.99 0.99 1 1
roup.
Table 4 Preliminary Results from INSIGHT*
Description N
Child (N = 211a)
Age at diagnosis (concurrent participants) 5.34 ± 3.81 years
Age at diagnosis (non-concurrent participants) 5.22 ± 3.98 years
Socio-Demographic Variables
Male 112 (60.2%)
Always speak English at home 129 (69.4%)




South Asian (India, Sri Lanka, etc) 39 (21.1%)
Asian/Pacific Islander 15 (8.1%)
Other 15 (8.1%)
Past Medical History
Gestational duration≥ 36 weeks 149 (81.42%)
Kidney problems at birth 4 (2.2%)
History of nephrotic syndrome: mother, father,
or sibling
3 (1.52%)
History of kidney disease: mother, father, or sibling 1 (0.5%)
History of kidney disease: extended family 151 (27.57%)
Parent or Caregiver (N = 209)
Socio-Demographic Variables
Parent use of interpreter to complete questionnaires 6 (6.4%)
Mother born in Canada 84 (45.4%)
Father born in Canada 78 (42.2%)
Families with combined income < $35,000 26 (27.66%)
Years of schooling, primary caregiver 14.5 ± 3.2 years
Age of mother at birth 31.3 ± 9.4 years
a Current as of August 14, 2012, with open enrollment.
* Numbers in this table may not add up to the specified N as data are not yet
available for all participants.
Hussain et al. BMC Nephrology 2013, 14:25 Page 7 of 11
http://www.biomedcentral.com/1471-2369/14/25Past medical history
Few participants report a history of kidney disease in the
immediate family. 81.4% of participants had a full gesta-
tional term of 36 weeks or greater. Only 2.2% (n = 4) of
participants report having had a kidney problem at birth.
The average age of the biological mother at birth was
31.3 ± 9.4 years.
Discussion
INSIGHT is a unique project that can: 1) address the
natural history of nephrotic syndrome from the time of
diagnosis, unlike other studies where participants are
recruited based on biopsy-proven diagnosis or treatment
response; 2) test the hypotheses of genetic risk factors
for nephrotic syndrome, not yet done in a large, multi-
ethnic cohort of children; and 3) increase understandingof social, clinical, and environmental factors that impact
self- and family-managed chronic disease in children
over the long term. The results of this study have the
potential to fill these gaps in current knowledge.
Understanding how social, environmental, clinical, and
genetic factors interact is important in order to truly
understand the pathogenesis of disease in a diverse popula-
tion of children. Nephrotic syndrome continues to be the
most commonly diagnosed kidney disease in children
worldwide. INSIGHT is an important and relevant project
as it will challenge our current understanding of the nat-
ural history of disease in the current era of newer steroid
sparing agents; in particular, the paradigm that initial re-
sponse to steroid treatment is the most important indicator
of disease progression [2]. Characterizing the risk of pro-
gression solely based on steroid treatment response ignores
other important risk factors that are potentially modifiable
and may influence overall outcome. Our current under-
standing of these additional risk factors is limited by previ-
ous study designs, follow-up, and use of selected populations.
Furthermore, INSIGHT is a timely project due to the recent
developments in genetic associations with nephrotic syn-
drome, and recent reports describing increased rates of dis-
ease over time [13,20,22,54,55].
Cohort studies on chronic diseases in children have
allowed us to better understand natural history of disease,
resulting in transformation to clinical practices. The Dia-
betes Chronic Complications Trial (DCCT) and its ancil-
lary study, Epidemiology of Diabetes Interventions and
Complications (EDIC), with ten years of intervention and
an additional ten years of observation demonstrated that
microalbuminuria could regress. This influenced how
patients were counselled and treated based on the assess-
ment of albuminuria [56,57]. Similarly, the Chronic Kid-
ney Disease in Children (CKiD) study, currently in its
sixth year and ongoing, follows children with mild to
moderate chronic kidney disease for factors influencing
disease progression, neurocognition, quality of life, cardio-
vascular health, and growth [58]. To date, CKiD has been
able to develop methods for calculating glomerular filtra-
tion rate (GFR) in children more accurately, and find asso-
ciations between GFR and sleep patterns, psychosocial
functioning, and neurocognitive delay. These factors have
not previously been recognized as significant comorbid
conditions associated with early declines in kidney func-
tion [58].
Specific to nephrotic syndrome, there are a few ongoing
cohort studies in progress, and it is anticipated that
INSIGHT will add complementary and additional infor-
mation to this body of work (see Table 5). PodoNet and
the UK Registry for Rare Kidney Diseases (RaDaR) are
both web-based registry studies on steroid resistant neph-
rotic syndrome, collect limited clinical data, and include
genetic testing for known genes associated with childhood
Table 5 Summary of Prospective Studies in Glomerular Research
Description INSIGHT Neptune PodoNet Radar
Target N 300a 450 1472b Not specified
# of centres 1a 15 85 Not specified
Length of follow-up 60 months 30 months Not specified Not specified










Ethnicity & immigration x Not specified
Birth history x
Family medical history x
Child allergy history x




McMaster Family Assessment Device (FAD) x
Reproductive history x
Health behaviour and social history (i.e. substance use) x
Quality of life x x
PROMIS Survey x
Beck Depression Inventory x
Modified Mini-Mental State Exam x
Parent or Caregiver Data
Demographics x
Ethnicity & immigration x
Family Environment x
McMaster Family Assessment Device (FAD) x
Patient Health Questionnaire for Depression and Anxiety
(PHQ-4)
x
Pregnancy information & assessment of in-utero
exposures
x
Parent perspectives on genetic testing x
Shortened Test of Functional Health Literacy Assessment
(S-TOFHLA)
x
Biorepository & Clinical Information
Ongoing assessment of relapses x Not specified Not specified
Medications history and changes x x Not specified
Standardized genetic workup x x
Blood collection x x x x
Urine collection x x x
Nail clipping x x
Clinical progress (unspecified) x x x x
a With ongoing recruitment and expansion.
b Current enrollment, unspecified target.
c Presumed MCNS, FSGS, MGN, MPGN.
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Nephrotic Syndrome Study Network (NEPTUNE) is a
prospective observational study where data collection
begins at the time of a clinically indicated renal biopsy,
after which they are followed for 30 months [61]. NEP-
TUNE and INSIGHT both assess quality of life and other
socio-demographic and environmental factors that may
influence, or be influenced by the progression of disease.
PodoNet, RaDaR, and NEPTUNE all focus on those with
established progressive disease sufficient to warrant a bi-
opsy, however, at this point worse disease outcomes and
factors likely influencing response may be missed.
INSIGHT recruits patients from the time of diagnosis
with idiopathic nephrotic syndrome, and follows the nat-
ural history of the disease course (Table 5).
INSIGHT is also the only study that examines the so-
cial determinants of health among children with neph-
rotic syndrome. The role of socio-demographic and
psychosocial factors have been shown or hypothesized to
influence health status among ESRD patients but there
are few observational cohort studies on children to ex-
plore the role of these factors in the earlier stages of kid-
ney disease before progression becomes a serious
concern [62,63]. As nephrotic syndrome in children is
largely managed at home, we are further limited by a
dearth of literature on interactions between a child and
caregiver. INSIGHT will help fill these gaps to help us
understand socio-demographic factors that influence
nephrotic syndrome, or are themselves influenced by dis-
ease progression.
There are limitations to the study which should be
addressed. As with all studies collecting questionnaire data
with personal and often sensitive information, some partici-
pants may be unwilling to provide information and will have
limited data. This study uses validated and reliable question-
naires as much as possible in order to minimize the risk of
inaccuracy and reduce the risk of measurement bias. Since
not all participants will get a biopsy, we can only presume
their pathological diagnosis is minimal change disease based
on estimates from prior studies [17]. The strengths of
INSIGHT are its large projected sample size, its lengthy pro-
jected follow-up time period, and its ethnically, socially, and
clinically diverse cohort, reflecting the diverse makeup of
Toronto. INSIGHT actively collects information from both
the parent and the child, allowing us to generate a holistic
picture of the role of the family and caregivers in the treat-
ment of nephrotic syndrome. The open enrollment structure
allows us to capture participants close to the time of clinical
presentation, with the aim of being able to establish factors
that truly influence the immediate progression of mild dis-
ease to more serious or chronic kidney disease.
Currently, INSIGHT is based in Toronto and efforts are
underway to expand the study to several partner sites
within Canada and internationally to allow for a large,ethnically diverse study population. As the study expands,
we anticipate that the ethnic makeup of our cohort will
become increasingly diverse, thus allowing us to better
test hypotheses of ethnic associations with disease. Estab-
lishing a global, multi-ethnic cohort requires some flexibil-
ity in the core data that can reasonably collected at each
site, particularly in sites in low- to middle-income coun-
tries where infrastructure to facilitate clinical research
may be minimal or non-existent and follow-up of partici-
pants may be more difficult.
Understanding the interaction between socio-demo-
graphic, environmental, clinical, and genetic factors asso-
ciated with disease susceptibility, steroid treatment resistance
and disease progression could lead to better screening strat-
egies at initial clinical presentation and ultimately more
refined treatment strategies overall. Results from INSIGHT
will lead to a better understanding of nephrotic syndrome in
the current era.
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